GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Net Change in Cash

Palatin Technologies (Palatin Technologies) Net Change in Cash : $-11.70 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Palatin Technologies's Net Change in Cash for the three months ended in Dec. 2023 was $3.96 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.70 Mil.

Palatin Technologies Net Change in Cash Historical Data

The historical data trend for Palatin Technologies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Net Change in Cash Chart

Palatin Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 39.34 -22.75 -30.17 -21.95

Palatin Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -1.55 -11.64 -2.46 3.96

Palatin Technologies Net Change in Cash Calculation

Palatin Technologies's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-28.419+-3.427+9.896+0
=-21.95

Palatin Technologies's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.476+9.462+4.974+0
=3.96

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palatin Technologies Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Palatin Technologies (Palatin Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Net Change in Cash
Comparable Companies
BIOR CDIO XLO IGXT TCRT NBIO BIVI INKT SRZN ACST OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
PTN:Germany PTN:Germany
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Website
https://www.palatin.com
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Executives
Stephen T Wills officer: Executive Vice President, CFO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana director, officer: President and CEO PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull director PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber director C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff director, officer: Exec. VP Research and Devel. C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Palatin Technologies (Palatin Technologies) Headlines

From GuruFocus

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

By PRNewswire PRNewswire • 05-16-2023

Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

By PRNewswire • 09-22-2023

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

By PRNewswire PRNewswire • 05-09-2023

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

By PRNewswire • 11-14-2023

Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi� Product Revenue Results

By PRNewswire • 07-11-2023

Palatin's Vyleesi� Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

By PRNewswire • 08-08-2023

Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

By PRNewswire PRNewswire • 05-08-2023

Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth� for Vyleesi�

By PRNewswire • 08-07-2023

Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

By PRNewswire • 10-18-2023

Thinking about buying stock in MedAvail Holdings, Trio-Tech International, Palatin Technologies, FlexShopper, or Silicom?

By PRNewswire • 08-08-2023